Clinical trials: Hyperactivity
Attention Deficit Hyperactivity Disorder
Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD
This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD.
- Trial name
- NCT00506285
- Testing
- Methylphenidate Transdermal System (MTS)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of Utah
Attention Deficit Hyperactivity Disorder
Sequencing Treatments for Mothers With ADHD and Their At - Risk Children
We hypothesize that successfully treating maternal Attention Deficit Hyperactivity Disorder (ADHD) will have a beneficial effect that extends to the child.
- Trial name
- TMF (NCT01816074)
- Testing
- Vyvanse (lisdexamphetamine), Behavior Parent Training
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Seattle Children's Hospital
ADHD
A Peer-Delivered High School Preparatory Intervention for Students With ADHD
This study will test whether a peer-delivered intervention for high school students with ADHD outperforms enhanced school services as usual.
- Trial name
- Summer STRIPES (NCT04571320)
- Testing
- Summer STRIPES, Enhanced School Services as Usual
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Seattle Children's Hospital
Attention Deficit Hyperactivity Disorder
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years
The objective of this study was to evaluate the plasma amphetamine concentration/time profile of amphetamine extended release oral suspension in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following…
- Trial name
- NCT03610464
- Testing
- Amphetamine Extended Release Suspension [Dyanavel]
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Attention Deficit Hyperactivity Disorder
Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed behavioral disorder in children. Prevalence rates in the United States range from 2% to 18% depending on diagnostic criteria and population studied.
- Trial name
- NCT01351064
- Testing
- CHICA ADHD Module
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Indiana University
ADHD
CTx-1301 Comparative Bioavailability Study
The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301.
- Trial name
- NCT04138498
- Testing
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder
Educating and Supporting Primary Care Providers in the Implementation of Evidence-based Practices for ADHD
Although numerous studies have demonstrated that a high percentage of primary care providers (PCPs) are knowledgeable about the American Academy of Pediatrics' guidelines for managing ADHD, many fail to implement these guidelines…
- Trial name
- NCT02271386
- Testing
- Supporting Practice for ADHD (SPA)
- Where
- United States
- Volunteers
- 895 people
- Sponsor
- Children's Hospital of Philadelphia
Attention Deficit Disorder With Hyperactivity
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine the effectiveness of behavioral treatment, drug treatment, and combined treatment for children with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00050622
- Testing
- Methylphenidate 0.15 mg/kg, Low-Intensity BMOD, Methylphenidate 0.3 mg/kg
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Florida International University
Hyperactive Delirium, Mixed Delirium
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Delirium is the most often encountered psychiatric diagnosis in the general hospital, with incidence up to 85% in the intensive care unit (ICU) setting and with significant consequences on patients' morbidity and mortality.
- Trial name
- NCT02343575
- Testing
- Valproic Acid, Haloperidol
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Adult Attention Deficit Hyperactivity Disorder
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.
- Trial name
- NCT03324581
- Testing
- OPC-64005, Atomoxetine
- Where
- 26 sites in United States
- Volunteers
- 239 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group study of dexmedetomidine versus placebo, with lorazepam rescue, for the management of severe alcohol withdrawal syndrome (AWS) and alcohol…
- Conditions
- Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
- Trial name
- NCT01362205
- Testing
- Dexmedetomidine
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Denver Health and Hospital Authority
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Bupropion for ADHD in Adolescents With Substance Use Disorder
Attention deficit hyperactivity disorder (ADHD) is one of the most common co-occurring psychiatric disorders (30-50%) in adolescents with substance use disorders (SUD).
- Conditions
- Attention Deficit Hyperactivity Disorder, Nicotine Dependence, Cannabis Use Disorder
- Trial name
- NCT00936299
- Testing
- Bupropion
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Colorado, Denver
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
ADHD
SPD544 High Strength Bioequivalence Study
The purpose of this study is to assess bioequivalence of 2 capsule strengths.
- Trial name
- NCT01183234
- Testing
- SPD544, Methylphenidate hydrochloride
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD.
- Trial name
- NCT02402166
- Testing
- SPD489
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
ADHD, Smoking
Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate whether Osmotic-Release Methylphenidate (OROS MPH), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation…
- Trial name
- NCT00253747
- Testing
- Osmotic-Release Methylphenidate
- Where
- 6 sites in United States
- Volunteers
- 255 people
- Sponsor
- University of Cincinnati
Attention Deficit Hyperactivity Disorder Symptoms
Implementation Strategy Resource Package for Behavioral Classroom Interventions: Pilot Test
The purpose of this study is to pilot test for feasibility and initial promise an implementation strategy resource package that aims to support teachers in using behavioral classroom management interventions for children with…
- Trial name
- NCT05489081
- Testing
- Positive Behavior Management Toolkit
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
ADHD
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
The primary objective of the study is to assess the efficacy and tolerability of a 12-week trial of memantine hydrochloride administered twice daily in 20 adults (ages 18-55) with ADHD and ADHD NOS.
- Trial name
- NCT00586573
- Testing
- memantine hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
ADHD
Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
This study will consist of a six-week open-label treatment period with an extended duration methylphenidate (OROS MPH) followed by subsequent monthly visits for 24 months in a large sample of youths aged 12-17 who meet Diagnostic…
- Trial name
- NCT00181714
- Testing
- methylphenidate HCl (Concerta)
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Massachusetts General Hospital
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning…
- Trial name
- NCT02096952
- Testing
- Methylphenidate extended-release liquid formulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital